Nattokinase and Cancer: Science & Japanese Breakfast

Nattō is a traditional Japanese breakfast food made from fermented soybeans. It's sticky, it smells strong, and most people outside Japan find it challenging to eat.

But the enzyme it produces — nattokinase — is catching the attention of cancer researchers worldwide.

Nattokinase is best known as one of nature's most powerful blood clot dissolvers. That alone makes it medically interesting. But scientists have now discovered something far more significant: it can physically break down the barriers that solid tumours build around themselves. Barriers that block your immune system. Barriers that block cancer drugs. Barriers that make tumours almost impossible to treat.

Nattokinase tears those barriers down.

Here's what the research shows — in plain language, with every study listed and linked.

---

8 Anti-Cancer Properties of Nattokinase — Explained

1. It Dissolves the Protective Coat That Hides Tumours

Many tumours wrap themselves in a protein called fibrin — the same stuff that forms blood clots. This fibrin coat acts like an invisibility cloak, hiding the tumour from your immune system and blocking oxygen from reaching it. Nattokinase dissolves fibrin. Strip away the cloak, and the tumour is exposed.

Nattokinase is a fibrinolytic enzyme — breaking down fibrin is literally what it was designed to do. In cardiovascular medicine, this makes it excellent for preventing dangerous clots. In cancer, that same ability targets the fibrin shell around tumours — potentially opening them up to immune attack and making cancer drugs more effective. This is the mechanism that originally drew cancer researchers to nattokinase.

2. It Breaks Down the Thick Walls Around Solid Tumours

Solid tumours surround themselves with a dense scaffolding of proteins called the extracellular matrix (ECM). Think of it as the tumour building its own fortress walls out of collagen and fibronectin. These walls are so thick that immune cells can't get in and cancer drugs can't penetrate. Nattokinase demolishes these walls.

This is one of the most exciting areas in cancer research right now. The ECM is a primary reason why immunotherapy fails in solid tumours — immune cells simply cannot physically reach the cancer cells. Nattokinase degrades the key ECM components, remodelling the entire tumour environment. Once the walls come down, everything changes — drugs get in, immune cells get in, and the tumour is suddenly vulnerable.

3. It Switches Cancer's Self-Destruct Programme Back On

Every cell in your body has a built-in self-destruct programme called apoptosis. It's how your body removes damaged or dangerous cells. Cancer cells switch this programme off so they never die. Nattokinase switches it back on — forcing cancer cells to self-destruct and stopping them from dividing.

Studies using human breast cancer cell lines showed nattokinase induces what's called G0/G1 cell cycle arrest — hitting the pause button on cell division — while simultaneously triggering apoptosis. It does this by modulating Bcl-2 family proteins: the on/off switch for the cell death programme. Shift the balance of these proteins, and cancer cells re-engage their self-destruct sequence and die.

4. It Suppresses the Key Proteins Tumours Use to Survive and Spread

Tumours produce specific proteins they use as tools — to grow, to migrate, to build new blood vessels. Four big ones are: CD44 (a "don't kill me" signal), FOXM1 (a cancer growth accelerator), vimentin (helps cancer cells move), and CD31 (builds new blood vessels). Nattokinase reduces all four — a simultaneous four-pronged attack on a tumour's survival toolkit.

Animal model studies demonstrated nattokinase limits tumour growth by modulating the expression of CD31, CD44, vimentin, and FOXM1 all at once. Reducing all four simultaneously disrupts the tumour's ability to grow, move, recruit blood supply, and evade immune destruction — all at the same time.

5. It Makes Chemotherapy Significantly More Effective

When nattokinase was combined with a common chemotherapy drug called oxaliplatin, the combination was significantly more powerful than oxaliplatin alone. More cancer cells died. The drug was absorbed better into cancer cells. The cancer couldn't migrate as easily. This suggests nattokinase could be used to enhance chemo — potentially allowing lower doses with fewer side effects.

The research showed the combination inhibited DNA synthesis in cancer cells more effectively than the drug alone, increased drug uptake, and more effectively blocked cell migration, invasion, and new blood vessel formation. The mechanism was confirmed by upregulation of three pro-death genes — BAD, BAX, and Caspase-3. When these genes activate, cancer cells die. Nattokinase helped flip those switches.

6. It Makes Radiation Therapy More Effective by Increasing Oxygen in Tumours

Radiation therapy damages cancer cells' DNA to kill them — but it works far better when there's plenty of oxygen present. Most solid tumours are deliberately low in oxygen (they create this condition to help themselves survive). By breaking down the dense tumour structure, nattokinase increases oxygen levels inside the tumour, making radiation dramatically more effective.

A 2023 study measured oxygen saturation levels in tumours before and after nattokinase pre-treatment. Oxygen levels rose significantly. When radiation therapy was then applied, results were markedly better than without nattokinase. This is a practical, elegant solution to one of radiotherapy's biggest limitations — and it requires nothing more than a natural enzyme.

7. It Supercharges Cancer Immunotherapy (CAR-T Cells)

CAR-T cell therapy is one of the most exciting cancer treatments in the world right now. It takes a patient's own immune cells, engineers them to hunt cancer, and sends them back in. The problem? In solid tumours, these supercharged immune cells can't get through the tumour's thick walls. Nattokinase dissolves those walls — and the CAR-T cells flood in and do their job.

A 2025 study testing nattokinase combined with MSLN-targeted CAR-T cells (targeting mesothelin — a protein on the surface of lung, breast, and mesothelioma cancers) found dramatically improved T cell infiltration into tumours, increased T cell persistence, and superior anti-tumour results compared to CAR-T cells alone. The idea that a fermented food enzyme could unlock the potential of immunotherapy in solid tumours is genuinely remarkable.

8. It Treats the Dangerous Blood Clots That Cancer Causes

Cancer patients have a very high risk of dangerous blood clots — called cancer-associated thrombosis, a leading cause of death in cancer patients. These clots don't just threaten life directly — they also physically block cancer drugs from reaching the tumour. Nattokinase dissolves these clots, opening pathways for treatment to work.

A 2024 study developed a nattokinase-heparin complex specifically for treating advanced tumour-related clots. It dissolved clots safely, improved drug delivery to tumour sites, and enhanced the anti-tumour effects of a co-administered chemotherapy drug. A separate study developed a nattokinase-polysialic acid complex designed to target clots specifically inside tumour blood vessels — unblocking the delivery routes for cancer drugs. Smart. Targeted. Natural.

---

So What Is the Bottom Line on Nattokinase and Cancer?

Nattokinase is not just a blood clot dissolver. It's emerging as a multi-purpose anti-cancer compound with abilities that conventional pharmaceuticals haven't been able to replicate: dismantling tumour barriers, boosting the immune system's access to cancer cells, sensitising tumours to radiation, enhancing chemotherapy, and potentially unlocking the full potential of CAR-T immunotherapy in solid tumours.

The most exciting possibility? That this humble fermented food enzyme could solve one of the biggest unsolved problems in oncology — the inability of treatments to penetrate solid tumour barriers.